Mylan and Biocon's European marketing application for Neulasta biosimilar accepted for review

• The European Medicines Agency accepts for review the Marketing Authorization Application filed by Mylan N.V. (MYL -1.4%) seeking approval of a biosimilar to Amgen's (AMGN) Neulasta (pegfilgrastim). Mylan co-developed the product candidate with Indian biopharma firm Biocon (OTC:BCNQY).